Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Inserm institut National De La Sante Et De La Recherche Medicale
Inserm institut National De La Sante Et De La Recherche Medicale Institut Pasteur And
Inserm institut National De La Sante Et De La Recherche Medicale_20100107
Inserm institut National De La Sante Et De La Recherche Medicale_20100121
Inserm institut National De La Sante Et De La Recherche Medicale_20100128
Inserm institut National De La Sante Et De La Recherche Medicale_20100114

Inserm institut National De La Sante Et De La Recherche Medicale patents


Recent patent applications related to Inserm institut National De La Sante Et De La Recherche Medicale. Inserm institut National De La Sante Et De La Recherche Medicale is listed as an Agent/Assignee. Note: Inserm institut National De La Sante Et De La Recherche Medicale may have other listings under different names/spellings. We're not affiliated with Inserm institut National De La Sante Et De La Recherche Medicale, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Inserm institut National De La Sante Et De La Recherche Medicale-related inventors


Synthetic single domain antibody

The invention relates to the identification of a highly stable single domain antibody scaffold (hs2d Ab) and its use in generating synthetic single domain antibody library (hs2d Ab-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.... Inserm institut National De La Sante Et De La Recherche Medicale

Polypeptides for engineering integrase chimeric proteins and their use in gene therapy

The present invention relates to polypeptide for engineering integrase chimeric proteins and their use in gene therapy. In particular, the present invention relates to a polypeptide which comprises the amino acid sequence ranging from the amino acid residue at position 617 to the amino acid residue at position 622 in... Inserm institut National De La Sante Et De La Recherche Medicale

Anaplerotic therapy of huntington disease and other polyglutamine diseases

The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine disease, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof.... Inserm institut National De La Sante Et De La Recherche Medicale

Anti-rho gtpase conformational single domain antibodies and uses thereof

The present invention relates to active form specific anti-Rho GTPase conformational single domain antibodies and their uses in particular in the therapeutic and diagnostic fields. In particular, the present invention relates to a single domain antibody wherein the amino acid sequences of CDR1-IMGT, CDR2-IMGT and CDR3-IMGT have at least 90%... Inserm institut National De La Sante Et De La Recherche Medicale

Methods for on demand pre-exposure prophylactic treatment of hiv infection

The present invention relates to methods for on demand pre-exposure prophylactic treatment of HIV infection. In particular, the present invention relates to a method for on demand pre-exposure prophylactic treatment of a subject at substantial risk for HIV infection comprising administering orally the subject with a combination of a therapeutically... Inserm institut National De La Sante Et De La Recherche Medicale

Methods for the diagnosis of pancreatic cancer

The present invention relates to the diagnosis of pancreatic cancer, in particular to a salivary mi RNA for use in the diagnosis of pancreatic cancer.... Inserm institut National De La Sante Et De La Recherche Medicale

Human monoclonal antibodies against orexin receptor type 1

The present disclosure relates to human monoclonal antibodies against orexin receptor type 1 (OX1R, hyprocretin 1) and uses thereof for the treatment of cancer. The antibodies are characterized by their CDRs: NYYMN, YISGSSRNIYYADFVKG, SNYDGMDV (Heavy chain) and AGTSSDVGGSNYVS, PGKAP, SSYTYYSTRV (Light Chain)) or the CDRS having at least 50% or... Inserm institut National De La Sante Et De La Recherche Medicale

Device for measuring the brain activity signals of an individual

Disclosed is a device suitable for measuring the brain activity signals of an individual, the device being intended to be placed on the head of the individual and having a structure intended to carry sensors, the structure allowing the position of the sensors to be adjusted. The structure of the... Inserm institut National De La Sante Et De La Recherche Medicale

Hpv particles and uses thereof

The invention relates to modified HPV particles that can be used therapeutically. Modified HPV particles may be used to deliver therapeutic agents, including siRNA molecules. Modified HPV particles may be used for the treatment of diseases or conditions of mucosal tissue, including HPV (human papilloma virus) infection and HPV-related tumors.... Inserm institut National De La Sante Et De La Recherche Medicale

Transgenic rpe cells overexpressing otx2 for the treatment of retinal degeneration

The present invention relates to methods and composition for use in the treatment of retinal degeneration, in particular retinal degeneration due to retinal pigment epithelium dysfunction.... Inserm institut National De La Sante Et De La Recherche Medicale

Methods for the prevention and the treatment of extracapillary glomerulonephritis

The present invention relates to the prevention and the treatment of extracapillary glomerulonephritis such as rapidly progressive glomerulonephritis and collapsing glomerulonephritis.... Inserm institut National De La Sante Et De La Recherche Medicale

Vibrotactile stimulation device

A vibrotactile stimulation device intended to be applied against a body environment (MC) to be stimulated and comprising a vibrating effector suitable for applying, to said environment, pulses of mechanical vibrational energy, and a controller controlling the effector according to stimulation rules. The device is remarkable in that it further... Inserm institut National De La Sante Et De La Recherche Medicale

Vibrotactile stimulation device

A vibrotactile stimulation device intended to be applied against a body medium (MC) to be stimulated, produced in the form of a functional unit, comprising a vibrating effector suitable for applying, to said medium, pulses of mechanical vibrational energy, and a controller for controlling the effector according to stimulation rules.... Inserm institut National De La Sante Et De La Recherche Medicale

Treatment of acute exacerbations of chronic obstructive pulmonary disease by antagonism of the il-20r

The present invention relates to methods and pharmaceutical compositions for the treatment of acute exacerbation of chronic obstructive pulmonary disease. In particular, the present invention relates to a method of treating acute exacerbation of chronic obstructive pulmonary disease in a subject in need thereof comprising administering the subject with a... Inserm institut National De La Sante Et De La Recherche Medicale

Methods and pharmaceutical compositions using orexins (oxa, oxb) for the treatment of prostate cancers

The present disclosure relates to methods and pharmaceutical compositions for the treatment of prostate cancers. In particular, the present invention relates to an OX1R agonist for use in the treatment of prostate cancer in a subject in need thereof.... Inserm institut National De La Sante Et De La Recherche Medicale

Cyclic antimicrobial pseudopeptides and uses thereof

The present invention provides cyclic antimicrobial pseudopeptides that are useful in a variety of applications. Also provided are pharmaceutical compositions, products and kits comprising such cyclic antimicrobial peptides and methods of using these antimicrobial peptides for modifying infectivity, killing microorganisms or inhibiting microbial growth or function and for preventing and/or... Inserm institut National De La Sante Et De La Recherche Medicale

Methods of diagnosing cancer and of predicting response of cancer to dendrogenin a treatment

The present invention relates to methods for the diagnosis and the treatment of cancer, in particular breast cancer. In particular, the present invention relates to a method of diagnosing cancer in a subject comprising the steps of i) determining the expression level of hGSTA1 in a tumor sample obtained from... Inserm institut National De La Sante Et De La Recherche Medicale

Methods and pharmaceutical composition for the preservation of vascular endothelial cell barrier integrity

The invention relates to an ANGPTL4 polypeptide for use in the preservation of vascular endothelial cell barrier integrity and reduction in no-reflow phenomenon with myocardial infarction.... Inserm institut National De La Sante Et De La Recherche Medicale

Polypeptides for the treatment of angiogenesis or lymphangiogenesis-related diseases

The present invention relates to polypeptides for the treatment of angiogenesis or lymphangiogenesis-related diseases. In particular, the present invention relates to a a polypeptide which comprises or consists of a sequence of at least 5 consecutive amino acids in SEQ ID NO: 1 and which comprises at least one amino... Inserm institut National De La Sante Et De La Recherche Medicale

Automated analyzing and interpreting an antimicrobial susceptibility

The present invention relates to a method of interpreting different antibiogram images in which it is possible to recognize a phenotype of bacterial resistance relative to antibiotics by comparing photographs using a photographic image bank of the reference antibiogram without any need to interpret them using the EUCAST or CA-SFM... Inserm institut National De La Sante Et De La Recherche Medicale

Pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning

The present invention relates to method and pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning. In particular, the present invention relates to a mineralocorticoid receptor antagonist for topical use in a method for preventing or reducing glucocorticoid-induced corneal or skin thinning in a subject in need thereof. The invention... Inserm institut National De La Sante Et De La Recherche Medicale

Antibodies directed against icos for treating graft-versus-host disease

The invention relates to a specific antibody directed against, for use for treating graft versus host disease.... Inserm institut National De La Sante Et De La Recherche Medicale

Methods and pharmaceutical compositions for treatment of cystic fibrosis

The present invention relates to a method and compositions for the treatment of cystic fibrosis.... Inserm institut National De La Sante Et De La Recherche Medicale

Combined use of a trka inhibitor and an epha2 inhibitor for using in the treatment of solid cancers, and the prognosis of survival of a patient who has a solid cancer

The invention relates to an EphA2 inhibitor for the use thereof in the treatment of solid cancer treated with a TrkA inhibitor, and a TrkA inhibitor for the use thereof in the treatment of solid cancer treated with an EpbA2 inhibitor. The invention also relates to a method for the... Inserm institut National De La Sante Et De La Recherche Medicale

Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors

The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation.... Inserm institut National De La Sante Et De La Recherche Medicale

Fluorinated pyridazin-3-ones for the use thereof in the treatment of lung diseases

The present invention concerns compounds belonging to the family of fluorinated pyridazin-3-ones, for the use thereof in the treatment of broncho-pulmonary conditions. In compounds having a formula, or a pharmaceutically acceptable salt of the compound, the formula includes R1 representing H, an alkyl, an aryl or a heteroaryl; either E2... Inserm institut National De La Sante Et De La Recherche Medicale

Methods and pharmaceutical compositions for the treatment of erythropoietic protoporphyria

The present invention relates to methods and pharmaceutical compositions for the treatment of Erythropoietic Protoporphyria. In particular, the present invention relates to a method for increasing the amount of functional FECH in a erythroid cell carrying the hypomorphic allele IVS3 48C/T (rs2272783) in trans to a deleterious mutation in the... Inserm institut National De La Sante Et De La Recherche Medicale

Antibodies directed against icos and uses thereof

The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which... Inserm institut National De La Sante Et De La Recherche Medicale

3-(4'-substituted)-benzyl-ether derivatives of pregnenolone

The invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt thereof: wherein R1 is C1-8 alkyl, C1-8 alkoxy, CN, NO2, amino, COOH, COOCH3, OH, N3, or halogen and R2 is H, OH, C1-8 alkyl, C1-8 alkoxy, C2-C6 alkenyl, halogen, Bn-O—, Bn- optionally substituted, or Ph- optionally... Inserm institut National De La Sante Et De La Recherche Medicale

Anti-neurotensin long fragment antibodies and uses thereof

The present invention relates to a neutralising antibody which is capable of binding to neurotensin with high affinity. The antibody of the present invention neutralises the activity of neurotensin, in particular the oncogenic activities of neurotensin. In particular, the present invention relates to a neutralising antibody which binds to the... Inserm institut National De La Sante Et De La Recherche Medicale

Human soluble cd146, preparation and uses thereof

The present invention relates to compositions and methods for modulating angiogenesis in vivo, ex vivo or in vitro. More particularly, the invention relates to a soluble CD146 protein usable in the context of human therapy, as well as to corresponding antibodies. Particular forms of CD146, herein described, may be used... Inserm institut National De La Sante Et De La Recherche Medicale

Methods for treating neuromuscular junction-related diseases

The present invention relates to methods for treating neuromuscular junction-related diseases. In particular, the present invention relates to a method of treating a neuromuscular junction-related disease in a subject in need thereof comprising ad ministering the subject with a therapeutically effective amount of at least one inhibitor of glycogen synthase... Inserm institut National De La Sante Et De La Recherche Medicale

2-oxo-3,4-dihydropyridine-5-carboxylates and their use

The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.... Inserm institut National De La Sante Et De La Recherche Medicale

Pharmaceutical compositions comprising agonists of orexin-1 receptor ox1r for the treatment of inflammatory bowel diseases

The present invention relates to methods and pharmaceutical compositions for the treatment of inflammatory bowel diseases. The presents methods relates to a method of treating an inflammatory bowel disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R agonist.... Inserm institut National De La Sante Et De La Recherche Medicale

Method for producing methane by means of aerobic co-culture of anaerobic micro-organisms

The present invention relates to the biological production of methane (Biogas) by co-culture in an aerobic atmosphere of a methanogenic bacterium and of an anaerobic bacterium capable of producing hydrogen, in a culture medium comprising or being supplemented with carbohydrate compound(s), notably starch and/or sugars, and supplemented with antioxidant compound(s).... Inserm institut National De La Sante Et De La Recherche Medicale

06/29/17 / #20170183662

Methods and compositions for treating neuropathic pain

The present invention relates to an inhibitor of FXYD2 gene expression for use in a method for treating neuropathic pain in a patient in need thereof. The invention also relates to a pharmaceutical composition comprising an inhibitor of FXYD2 gene expression, wherein said pharmaceutical composition is formulated for a direct... Inserm institut National De La Sante Et De La Recherche Medicale

06/29/17 / #20170183620

Use of uric acid for culturing bacteria sensitive to oxygen tension

The present invention relates to a method for cultivating in vitro in an acellular culture medium, bacteria for which the growth is sensitive to oxygen content, said bacterium being selected from anaerobic bacteria and intracellular micro-aerophilic bacteria, characterized in that uric acid is added into said acellular culture medium, and... Inserm institut National De La Sante Et De La Recherche Medicale

06/29/17 / #20170183662

Methods and compositions for treating neuropathic pain

The present invention relates to an inhibitor of FXYD2 gene expression for use in a method for treating neuropathic pain in a patient in need thereof. The invention also relates to a pharmaceutical composition comprising an inhibitor of FXYD2 gene expression, wherein said pharmaceutical composition is formulated for a direct... Inserm institut National De La Sante Et De La Recherche Medicale

06/29/17 / #20170184566

Methods for determining whether a patient will achieve a response after radiation therapy

Disclosed are methods for determining whether a patient will achieve a response after radiation therapy, in particular a method for determining whether a patient suffering from a cancer will achieve a response after radiation therapy including the steps of i) determining the level of ceramide in a first blood sample... Inserm institut National De La Sante Et De La Recherche Medicale

06/22/17 / #20170175107

Methods for selecting binders by phage display and masked selection

The present invention relates to methods for selecting binders by phage display and masked selection. More particularly, the present invention relates to a method for selecting a plurality of binders specific for at least one relevant target comprising screening a phage binder library of binders against the relevant target in... Inserm institut National De La Sante Et De La Recherche Medicale

06/22/17 / #20170176417

Method and pharmaceutical composition for use in the treatment of neurodegenerative disorders

The invention relates to compounds which activate the BASIGIN signalling pathway, preferably agonists of BASIGIN, for the treatment of neurodegenerative disorders.... Inserm institut National De La Sante Et De La Recherche Medicale

06/22/17 / #20170176446

Methods for determining the oncogenic condition of cell, uses thereof, and methods for treating cancer

The invention relates to methods for detecting the oncogenic condition of cells, including step where the amount of the OCDO compound in said cells is measured, and to the uses thereof. The invention further relates to OCDO inhibitors for use in methods for treating cancer.... Inserm institut National De La Sante Et De La Recherche Medicale

06/15/17 / #20170166892

Methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis

The present invention relates to methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis. In particular, the present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing cardiovascular fibrosis in a subject in need thereof.... Inserm institut National De La Sante Et De La Recherche Medicale

05/25/17 / #20170145423

Use of mcoln-1 modulators to regulate cell migration

The present invention relates to the use of modulators of Mcoln-1 for modulating the cells migration, in particular the migration of dendritic cells and tumor cells, especially for antitumoral vaccination, autoimmune diseases treatment, and metastasis prevention.... Inserm institut National De La Sante Et De La Recherche Medicale

05/18/17 / #20170137419

Derivatives of 2h-pyrazolo[4,3-c]quinolin-3(5h)-one and use thereof

The invention relates to compounds of formula (I) or the pharmaceutically acceptable solvates thereof, as well as to the use thereof as a drug.... Inserm institut National De La Sante Et De La Recherche Medicale

05/11/17 / #20170128433

Inhibitors of the pp1/gadd34 complex for the treatment of a condition requiring an immunosuppressive activity

The present invention relates to the general field of treatment and prevention of diseases involving an inflammatory condition, namely sepsis or infectious or viral diseases as well as diseases requiring for the treatment of immunosuppressive activity namely autoimmune diseases and graft rejection. In particular, the invention relates to an inhibitor... Inserm institut National De La Sante Et De La Recherche Medicale

05/11/17 / #20170131285

Methods and compositions for diagnosing, monitoring and treating cancer

The invention relates to methods for diagnosing cancer and determining the responsiveness to chemotherapyin a subject based on the detection of HSP70-expressing exosomes in a bodily fluid sample obtained from said subject. The invention also relates to methods for treating cancer and in particular methods for restoring or enhancing the... Inserm institut National De La Sante Et De La Recherche Medicale

04/27/17 / #20170114113

Polypeptides as apelin inhibitors and uses thereof

The present invention relates to polypeptides and their uses as apelin inhibitors. More particularly, the present invention relates to a polypeptide comprising the sequence as set forth in SEQ ID NO:1 wherein at least one arginine residue at position 18, 19, 22 or 23 has been substituted or deleted.... Inserm institut National De La Sante Et De La Recherche Medicale

03/09/17 / #20170067053

Methods for preventing and treating chronic kidney disease (ckd)

The present invention relates to methods for preventing and treating chronic kidney disease (CKD).... Inserm institut National De La Sante Et De La Recherche Medicale

03/09/17 / #20170067105

Methods for selecting competent oocytes and competent embryos with high potential for pregnancy outcome

The present invention relates to a method for selecting a competent oocyte or a competent embryo by determining the expression level of specific microRNA species in a body fluid or in cumulus cells.... Inserm institut National De La Sante Et De La Recherche Medicale

02/23/17 / #20170049854

Methods and pharmaceutical compositions for the cardioprotection

The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a ligand of the sonic hedgehog signaling pathway for use in the cardioprotection of a subject who experienced a myocardial infarction.... Inserm institut National De La Sante Et De La Recherche Medicale

02/23/17 / #20170049862

Methods and pharmaceutical compositions for treating vaso-occlusive crisis

The present invention relates to methods and pharmaceutical compositions for treating vaso-occlusive crises. In particular, the present invention relates to a method of treating a vaso-occlusive crisis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of agent capable of degrading, destabilizing or depleting... Inserm institut National De La Sante Et De La Recherche Medicale

02/23/17 / #20170051062

Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway

The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and... Inserm institut National De La Sante Et De La Recherche Medicale

02/23/17 / #20170052202

Methods for diagnosing and treating iron dysregulation

The present invention relates to methods for diagnosing and treating iron overload and iron deficiency.... Inserm institut National De La Sante Et De La Recherche Medicale

02/16/17 / #20170044234

Polypeptides and uses thereof for reducing cd95-mediated cell motility

The present invention relates to polypeptides and uses thereof for reducing CD95-meditated cell motility. In particular, the present invention relates to a polypeptide having an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino-acid residue at position 175 to the amino-acid... Inserm institut National De La Sante Et De La Recherche Medicale

02/16/17 / #20170044533

Methods for the treatment of leber congenital amaurosis

The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of... Inserm institut National De La Sante Et De La Recherche Medicale

01/26/17 / #20170020847

Methods and pharmaceutical compositions for the treatment of beta-thalassemias

The present invention relates to methods and pharmaceutical compositions for the treatment of beta-thalassemias. In particular, the present invention relates to an XPO1 inhibitor for use in a method for treating beta-thalassemia in a subject in need thereof.... Inserm institut National De La Sante Et De La Recherche Medicale

01/19/17 / #20170014426

Ulipristal acetate for prevention and treatment of breast tumors

The invention relates to the use of ulipristal acetate, or any of its metabolites, in preventing or treating a breast tumor in a patient, preferably a patient that carries a mutation in BRCA1 gene.... Inserm institut National De La Sante Et De La Recherche Medicale








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Inserm institut National De La Sante Et De La Recherche Medicale in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Inserm institut National De La Sante Et De La Recherche Medicale with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###